124 results on '"de Las Heras B"'
Search Results
2. Selective sentinel node biopsy after intratumour administration of radiotracer in breast cancer patients treated with neoadjuvant chemotherapy in relation to the level of tumor response
3. 108P Pathologic nodal positivity in patients with cT1-2 cN0 HER2+ breast cancer treated with upfront surgery or neoadjuvant anti-HER2-based therapy
4. 95P PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study
5. 14P Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO
6. 93MO Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
7. 62P Outcomes of high-risk breast cancer (BC) patients from El Álamo IV registry and GEICAM adjuvant clinical trials
8. 208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial
9. Methodological advances in the discovery of novel neuroblastoma therapeutics
10. Outcomes of high-risk breast cancer (BC) patients from El Alamo IV registry and GEICAM adjuvant clinical trials
11. SHORT-TERM PROTECTIVE EFFECTS OF DEHYDROHISPANOLONE ON MYOCARDIAL INFARCTION IN RATS: C007
12. Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR) [+]/HER2[-] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA
13. MR Denoising Increases Radiomic Biomarker Precision and Reproducibility in Oncologic Imaging
14. 129TiP Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR)[+]/HER2[–] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA
15. 130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype
16. The economic burden of metastatic breast cancer in Spain
17. A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting
18. 319P Prognosis for patients with oligometastatic breast cancer who achieve NED status after systemic and local therapy
19. 354TiP Unraveling trastuzumab emtansine resistance in HER2-positive advanced breast cancer: GEICAM KATIA study
20. 180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial
21. 101P Predictors of 18F-fluorodeoxyglucose (F) positron-emission tomography (PET)-driven disease detection in patients (pts) with HER2[+] early breast cancer (EBC). A substudy of the PHERGain trial
22. 143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
23. As décadas do silêncio: a representação dos imigrantes no Brasil entre as duas guerras mundiais
24. Abstract OT3-02-05: CORALLEEN: A phase 2 clinical trial of chemotherapy or letrozole plus ribociclib as neoadjuvant treatment for postmenopausal patients with luminal B/HER2-negative breast cancer
25. Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
26. Abstract P3-12-01: 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitors (AIs) in the adjuvant setting. A phase II prospective, randomized, double-blind placebo-controlled study - “the Blissafe study”
27. AXL as a potential primary and secondary trastuzumab resistance mechanism in breast cancer cells with HER2 overexpression
28. SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer
29. Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
30. Detección selectiva del ganglio centinela tras administración intratumoral del radiotrazador, en pacientes con cáncer de mama tratadas con quimioterapia neoadyuvante en relación con el grado de respuesta tumoral
31. Novel Water-Soluble Mucoadhesive Carbosilane Dendrimers for Ocular Administration
32. Diffuse cutaneous mastocytosis. Presentation of 3 cases and therapeutic management review
33. Mastocitosis cutánea difusa. Presentación de 3 casos y revisión de su manejo terapéutico
34. 72O - Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
35. 321TiP - SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer
36. 155PD - Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
37. 13P - AXL as a potential primary and secondary trastuzumab resistance mechanism in breast cancer cells with HER2 overexpression
38. Design and Characterization of an Ocular Topical Liposomal Preparation to Replenish the Lipids of the Tear Film
39. Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months
40. PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers
41. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
42. Cardiorespiratory Fitness Benefits of High-Intensity Interval Training After Stroke: A Randomized Controlled Trial.
43. Reproducibility Analysis of Radiomic Features on T2-weighted MR Images after Processing and Segmentation Alterations in Neuroblastoma Tumors.
44. Imaging biomarkers and radiomics in pediatric oncology: a view from the PRIMAGE (PRedictive In silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers) project.
45. Measuring Neuroplasticity in Response to Cardiovascular Exercise in People With Stroke: A Critical Perspective.
46. Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy.
47. Gaming in Pandemic Times: An International Survey Assessing the Effects of COVID-19 Lockdowns on Young Video Gamers' Health.
48. Independent Validation of a Deep Learning nnU-Net Tool for Neuroblastoma Detection and Segmentation in MR Images.
49. Phenolic and quinone methide nor-triterpenes as selective NLRP3 inflammasome inhibitors.
50. Synthesis of Quinoline and Dihydroquinoline Embelin Derivatives as Cardioprotective Agents.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.